Johnson & Johnson faces price negotiation challenges from Medicare as MFN policy limits prices paid by government programs.
1 report, 1 independent
Updated May 26
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Johnson & Johnson faces price negotiation challenges from Medicare as MFN policy limits prices paid by government programs.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Johnson & Johnson fits the profile of investments monitored under Medicare rules.Sub-event
- Medicare premiums are impacting the dividend yields of Johnson & Johnson.Sub-event
JNJ faces price negotiation challenges from Medicare due to MFN policy limits on government program payments.1 source
Keep exploring
The entities involved
-
Medicare
US federal health insurance
-
Johnson & Johnson
U.S multinational medical devices, pharmaceutical and consumer packaged goods manufacturer
-
Intuitive Surgical
American corporation
Related events
- FDA approval enabled TAVR procedure, with Medicare conditioning payment on STS requirements.
- CMS introduced the Medicare drug price negotiation program, and companies are facing challenges regarding pricing and market access.
- Corporate activity in the medical device sector in August 2025 included M&A activity (Stryker/Inari Medical, ZimVie/Archimed), competition between Medtronic and Intuitive Surgical, and the impact of Trump administration tariffs and FDA reviews.
- Government negotiates cost caps for Medicare patients.